Active Biotech AB (publ) (OM: ACTI)
Health Care · Biotechnology · SE
Skr5.30
+2.12% today · -69.4% 1Y
Active Biotech AB (publ) (OM: ACTI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.75M and employs 5 people.
Over the last twelve months the share price has lost 69.4%, trading between 3.70 and 22.00.
Tweenvest scores Active Biotech AB (publ) across four factors: quality 30/100. Its strongest factor is quality.
ACTI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.75M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.79
- Dividend yield
- —
- Beta (5Y)
- 1.34
- 52-week high
- Skr22.00
- 52-week low
- Skr3.70
- Avg volume (3M)
- —
- Shares outstanding
- 26.36M
- Employees
- 5
- Next earnings
- —
About Active Biotech AB (publ)
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
- ISIN
- SE0029278555
- Founded
- 1983
- Listed since
- Dec 19, 2003
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.